• US$500,000 upon exercising of the option to acquire all rights, title, and interest in the galidesivir program. • US$500,000 upon completion of Phase 2 clinical trial. • US$1M upon approval of New Drug Application in US or equivalent or US$1.5M upon Animal Rule approval in which no Phase 2 is required. • Tiered royalties of 5-10% of Net Sales • 25% of proceeds from sale of any Priority Review Voucher awarded due to FDA approval of the acquired program
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
-0.015(10.0%) |
Mkt cap ! $31.87M | |||
| Open | High | Low | Value | Volume |
| 15.0¢ | 15.0¢ | 13.0¢ | $52.62K | 392.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 461802 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.48pm 27/06/2025 (20 minute delay) ? |
| ILA (ASX) Chart |